Background/Aims: Mounting evidence suggests that epitranscriptional modifications regulate multiple cellular processes. N 6 -Methyladenosine (m 6 A), the most abundant reversible methylation of mRNA, has critical roles in cancer pathogenesis. However, the mechanisms and functions of long non-coding RNA (lncRNA) methylation remain unclear. Pancreatic cancer resulted in 411,600 deaths globally in 2015. By the time of pancreatic cancer diagnosis, metastasis has often occurred in other parts of the body. The present study sought to investigate lncRNA m6A modification and its roles in pancreatic cancer. Methods: Differential expression between cancer cells and matched normal cells was evaluated to identify candidate lncRNAs. The lncRNA KCNK15-AS1 was detected in cancer tissues and various pancreatic cells using RT-qPCR. KCNK15-AS1 was transfected into cells to explore its role in migration and invasion. Then, m 6 A RNA immunoprecipitation was performed to detect methylated KCNK15-AS1 in tissues and cells. Epithelial-mesenchymal transition (EMT) markers were used to evaluate KCNK15-AS1-mediated EMT processes. Results: KCNK15-AS1 was downregulated in pancreatic cancer tissues compared with paired adjacent normal tissues. KCNK15-AS1 inhibited migration and invasion in MIA PaCa-2 and BxPC-3 cells. Furthermore, total RNA methylation in cancer cells was significantly enriched relative to that in immortalized human pancreatic duct epithelial (HPDE6-C7) cells. In addition, the m 6 A eraser ALKBH5 was downregulated in cancer cells, which can demethylate KCNK15-AS1 and regulate KCNK15-AS1-mediated cell motility. Conclusion: Our results have revealed a novel mechanism by which ALKBH5 inhibits pancreatic cancer motility by demethylating lncRNA KCNK15-AS1, identifying a potential therapeutic target for pancreatic cancer.
Introduction
Pancreatic cancer is one of the most aggressive types of cancer and is the sixth leading cause of cancer-related deaths in China [1] and the seventh worldwide [2] , respectively. It causes 330, 000 deaths annually and constitutes a notable global health problem [2] . Pancreatic cancer has an extremely poor prognosis, with a median survival of 5 to 8 months (less than 10% survival rate). Pancreatic cancer develops with variable symptoms, local invasiveness, or metastases to distant sites in its early stages [3] . Accordingly, it is important to investigate the mechanisms that contribute to metastasis in pancreatic cancer.
Long non-coding RNAs (lncRNAs) are non-coding RNAs comprising more than 200 nucleotides that lack protein coding capacity. Mounting evidence has demonstrated that lncRNAs play important roles in cancer cell proliferation, apoptosis, and metastasis. Although HOTAIR [4] , HOTTIP [5] , and MALAT1 [6] have been reported in pancreatic cancer studies, the mechanisms by which lncRNAs regulate pancreatic cancer require further exploration.
More than 100 RNA modifications have been reported [7] , but there are few reports on lncRNA modifications. N 6 -methyladenosine (m 6 A) modification is the most common internal modification in eukaryotic mRNAs [8] . Two recently identified mammalian RNA demethylases, the fat mass and obesity-associated protein (FTO) and alkylation repair homolog protein 5 (ALKBH5), have demonstrated that the m 6 A methylation modification is a dynamic and reversible process. However, the mechanism by which FTO and ALKBH5 regulate lncRNA methylation requires further investigation.
In this study, we demonstrate that the lncRNA KCNK15-AS1 is significantly downregulated in pancreatic cancer, revealing its inhibitory functions on cell migration and invasion. Additionally, the m 6 A eraser ALKBH5 was found to be downregulated in cancer tissues, where it could demethylate KCNK15-AS1 and regulate KCNK15-AS1 expression. ALKBH5 was also found to be involved in KCNK15-AS1-mediated cell migration and invasion. In the future, ALKBH5-KCNK15-AS1 might serve as a therapeutic target for patients with pancreatic cancer.
Materials and Methods

Clinical samples
Fresh frozen pancreatic cancer tissues and their adjacent normal tissues were obtained from the First Affiliated Hospital of Nanjing Medical University. The samples were obtained within 10 min after tumor excision and immediately stored at -80°C until use in experiments. Written informed consent was obtained from all patients, and this study was approved by the Ethics Committee of the hospital (2017-SR-171).
Microarray analysis
Total RNA was extracted from three pancreatic cancer tissues and paired adjacent normal tissues, and the expression profile of 30, 584 human lncRNAs was determined using Arraystar Human LncRNA Microarray V3.0. Volcano plot filtering, set at a threshold of ≥2.0-fold, was used to screen for lncRNAs that exhibited significantly different (P < 0.05; unpaired t-test) expression levels in the two study groups.
Cell culture and cell transfection
Human pancreatic cancer cell lines (MIA-PaCa-2 and BxPC-3) and human embryonic kidney cells (293T) were purchased from the American Type Culture Collection (ATCC, Manassas, VA), and the immortal human pancreatic duct epithelial cell line (HPDE6-C7), which is considered a normal pancreatic cell line, was obtained from the Pancreas Institute, Nanjing Medical University. HPDE6-C7, MIA-PaCa-2, and BxPC-3 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin. All cell lines were cultured in an atmosphere of 5% CO 2 and 99% relative humidity at 37°C. Lipofectamine 2000™ was applied to conduct transfections in accordance with the manufacturer's guidelines (Invitrogen, Carlsbad, CA).
RNA isolation and reverse transcription
Total RNA was isolated from cells and tissues using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The NanoDrop ND2000 (Thermo Scientific Inc., Waltham, MA) was used to determine RNA purity and to quantify RNA concentration. A First Strand cDNA Synthesis Kit (TaKaRa, Beijing, People's Republic of China) was used to perform reverse transcription.
Real-time quantitative polymerase chain reaction
Real-time quantitative polymerase chain reaction (RT-qPCR) primers were obtained from GenScript (Nanjing, People's Republic of China), and the sequences are listed in Table 1 . According to the manufacturer's instructions, RT-qPCR was performed using the SYBR Prime-Script RT-PCR Kit (Takara Biomedical Technology (Beijing) Co., Ltd., Beijing, China) with a Roche LightCycler 96 fluorescent quantitative PCR system (Roche, Mannheim, Germany). The reaction started at 95°C for 5 min, followed by 40 cycles of 95°C for 30 s, 59°C for 30 s, and 72°C for 30 s. Actin was used as the internal control to normalize qPCR results. Relative gene expression levels were measured using cycle threshold (CT) values in the ΔΔCT calculation [4] .
Cell migration and invasion assay
Transwell assays were conducted with an 8-μm pore size insert with or without Matrigel Invasion Chambers (Millipore Corporation, Burlington, MA) to evaluate the properties of migration or invasion of pancreatic cells. Then, 48 h post-transfection, single-cell suspensions were seeded into the upper chamber, and the lower chamber was filled with 500 μL of Dulbecco's Modified Eagle's Medium containing 10% FBS. After the indicated incubation time, the non-migrating or invading cells were wiped from the upper surface of the membranes, and cells were stained with 2% crystal violet solution after fixation in methanol. Images of migrated cells in each well were captured and counted in random fields using a microscope. Each experiment was conducted in triplicate.
Western blotting and antibodies
Total protein (60 μg) was subjected to SDS-PAGE and transferred to a 0.45-μm PVDF membrane (Millipore Corporation). Antibodies against ALKBH5 (Abcam, Cambridge, MA; 1:100) and actin (Santa Cruz Biotechnology, Santa Cruz, CA; 1:2000) were used. Membranes were incubated overnight at 4°C with primary antibodies diluted 1:1, 000 to 1:10, 000 according to the manufactures' instructions, and proteins were detected with a peroxide LumiGLO reagent (Cell Signaling Technology, Danvers, MA).
RNA immunoprecipitation
RNA immunoprecipitation (RIP) experiments were performed using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore Corporation). Antibodies against m 6 A (Abcam) or control proteins were diluted to 1:50. Total RNA (input control) and precipitation with the isotype control (IgG) for each antibody were assayed simultaneously. The co-precipitated RNAs were detected by qRT-PCR.
Confocal microscopy
Cells were fixed with 4% paraformaldehyde in PBS at room temperature for 10 min and permeabilized with 0.1% Triton-X and 1% BSA in PBS for 30 min at room temperature. DNA was stained using 4',6-diamidino-2-phenylindole (DAPI). KCNK15-AS1 antisense probe hybridization was performed at 37°C for about 16 h to detect KCNK15-AS1. The sequences of probes are listed in Table 2 . Imaging was performed using a Zeiss Axiovert 200M laser scanning confocal microscope (Carl Zeiss AG, Oberkochen, Germany). 
Results
LncRNA KCNK15-AS1 is downregulated in pancreatic cancer tissues and cells
To acquire the transcriptional profile of lncRNAs in pancreatic cancer, paired pancreatic cancer tissues and normal tissues (n = 3) were analyzed using ArrayStar lncRNA microarrays. We identified seven candidate lncRNAs (Fig. 1A) that were deregulated significantly between cancer and paired normal tissues. Some of these lncRNAs have previously been investigated in other cancer types, but no published studies have focused on KCNK15-AS1. We examined KCNK15-AS1 expression in 69 paired clinical pancreatic cancer and normal tissues (Fig. 1B) . KCNK15-AS1 was downregulated in cancer tissues compared with paired normal tissues. Then, we compared the KCNK15-AS1 expression levels in normal pancreatic ductal epithelial cells (HPDE6-C7) and pancreatic cancer cells (BxPC-3, MIA-PaCa-2, AsPC-1, and PANC-1). BxPC-3 and MIA-PaCa-2 had the lowest KCNK15-AS1 expression levels among all cells (Fig. 1C) . Thus, we used BxPC-3 and MIA-PaCa-2 to investigate the role of KCNK15-AS1 in pancreatic cancer pathogenesis.
KCNK15-AS1 inhibits cell migration and invasion
To investigate the regulatory function of KCNK15-AS1, we overexpressed KCNK15-AS1 in BxPC-3 and MIA-PaCa-2 cells (Fig. 2A) . Because metastasis is the most malignant feature of pancreatic cancer, we first evaluated cell motility after inducing KCNK15-AS1. The results showed that overexpression of KCNK15-AS1 in MIA-PaCa-2, resulted in significantly reduced migrating and invading cells (P < 0.001) (Fig. 2B  and C) . Similar results were observed for BxPC-3 cells (Fig. 2D and E) . A enrichment was highest in MIA-PaCa-2 and BxPC-3 cells (Fig. 3A) . ALKBH5 is a well-characterized RNA m 6 A demethylase; accordingly, we examined ALKBH5 expression levels in HPDE6-C7, MIAPaCa-2, and BxPC-3 cells. The western blots indicated that ALKBH5 is downregulated in MIA-PaCa-2 and BxPC-3 cells (Fig. 3B) . Confocal laser scanning microscopy revealed that the m 6 A signal colocalized with KCNK15-AS1 (Fig. 3C) , indicating that KCNK15-AS1 undergoes m 6 A modification. To investigate whether KCNK15-AS1 is regulated by ALKBH5, we overexpressed ALKBH5 in BxPC-3 and MIAPaCa-2 cells (Fig. 4A) . As A modification decreased after ALKBH5 overexpression (Fig. 4B) . Based on RT-qPCR, KCNK15-AS1 expression was elevated when ALKBH5 was overexpressed in MIA-PaCa-2 and BxPC-3 cells (Fig. 4C) . We detected a linear correlation 
Discussion
LncRNAs regulate different aspect of cellular processes including metastasis of cancer cells. Cytoplasmic and nuclear lncRNAs function differently according to the cellular distribution of lncRNAs [9] [10] [11] . Cytoplasmic lncRNAs often regulate protein biosynthesis [12] , while nuclear lncRNAs tend to affect mRNA transcription and/or alternative splicing [13, 14] . However, the role of nuclear lncRNAs in epitranscriptional modification remains unclear. In this study, we identified KCNK15-AS1, a lncRNA significantly decreased in pancreatic cancer tissues and inhibited cell migration and invasion.
Recent studies have shown that the m 6 A mRNA modification is important for the stability mRNA [15] , and m 6 A methylation is a post-transcriptional modification of RNA occurring in the nucleus [16] . RNA m 6 A methylation is reversible and can be demethylated by ALKBH5 or FTO [17, 18] . The m 6 A mRNA modification has been studied extensively; however, the importance of lncRNA methylation has remained elusive [19] . We found that KCNK15-AS1 underwent m 6 A methylation in pancreatic cells HPDE6-C7, MIA-PaCa-2, and BxPC-3. KCNK15-AS1 could be demethylated by ALKBH5. Moreover, KCNK15-AS1 m 6 A methylation was negatively correlated with its expression level.
Although ALKBH5 is known to regulate m 6 A modification [20] , the functions of ALKBH5 in pancreatic cells remain unclear. To address this, we overexpressed ALKBH5 in MIA-PaCa-2 and BxPC-3 cells, demonstrating that ALKBH5 could inhibit cell migration and invasion.
In this study, we found a significant decrease in the expression of lncRNA KCNK15-AS1 in pancreatic cancer tissues. This exerted an inhibitory effect on cell motility. Furthermore, KCNK15-AS1 was demethylated by ALKBH5 and was negatively correlated with m 6 A modification (Fig. 6D) . It is possible that m 6 A could affect the stability of KCNK15-AS1 based on RNA m 6 A analyses, but the mechanism remains unclear. We also report the novel observation that lncRNA can undergo methylation. We will investigate the potential clinical importance of lncRNA methylation and modifiers of their methylation in future research. Our data could be further developed as a valuable therapeutic strategy for pancreatic cancer prevention and control.
